| Upgrades | Hold Buy | X | ||
|
$2 $3 |
||||
| Downgrades | Buy Hold | X | ||
|
$12 $2 |
||||
| Downgrades | Buy Hold | X | ||
|
$10 $14 |
||||
| Upgrades | Hold Buy | X | ||
|
$8 $18 |
||||
| Downgrades | Buy Hold | X | ||
|
$65 $25 |
||||
| Resumed | Outperform | X | ||
| Resumed | Outperform | X | ||
| Initiated | Buy | X | ||
| Initiated | Buy | X | ||
ALXO ALX Oncology Holdings Inc
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
